CVE-2017-2816

Public Exploit

Description

An exploitable buffer overflow vulnerability exists in the tag parsing functionality of LibOFX 0.9.11. A specially crafted OFX file can cause a write out of bounds resulting in a buffer overflow on the stack. An attacker can construct a malicious OFX file to trigger this vulnerability.

Category

8.8
CVSS
Severity: High
CVSS 3.1 •
CVSS 3.0 •
CVSS 2.0 •
EPSS 0.75% Top 30%
Vendor Advisory gentoo.org
Affected: LibOFX LibOfx
Published at:
Updated at:

References

Link Tags
https://lists.debian.org/debian-lts-announce/2017/11/msg00038.html third party advisory mailing list
http://www.securityfocus.com/bid/100828 broken link third party advisory vdb entry
https://security.gentoo.org/glsa/201908-26 third party advisory vendor advisory
https://www.talosintelligence.com/vulnerability_reports/TALOS-2017-0317 third party advisory exploit technical description

Frequently Asked Questions

What is the severity of CVE-2017-2816?
CVE-2017-2816 has been scored as a high severity vulnerability.
How to fix CVE-2017-2816?
To fix CVE-2017-2816, make sure you are using an up-to-date version of the affected component(s) by checking the vendor release notes. As for now, there are no other specific guidelines available.
Is CVE-2017-2816 being actively exploited in the wild?
It is possible that CVE-2017-2816 is being exploited or will be exploited in a near future based on public information. According to its EPSS score, there is a ~1% probability that this vulnerability will be exploited by malicious actors in the next 30 days.
What software or system is affected by CVE-2017-2816?
CVE-2017-2816 affects LibOFX LibOfx.
This platform uses data from the NIST NVD, MITRE CVE, MITRE CWE, First.org and CISA KEV but is not endorsed or certified by these entities. CVE is a registred trademark of the MITRE Corporation and the authoritative source of CVE content is MITRE's CVE web site. CWE is a registred trademark of the MITRE Corporation and the authoritative source of CWE content is MITRE's CWE web site.
© 2025 Under My Watch. All Rights Reserved.